T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc..
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T cell clone was identified at low levels in the blood before CAR T infusion and in lung cancer. To assess the overall risk of secondary primary malignancy after commercial CAR T (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had a secondary primary malignancy. The median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL after CAR T.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Nature medicine - 30(2024), 4 vom: 01. Apr., Seite 984-989 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD19 |
|---|
| Anmerkungen: |
Date Completed 22.04.2024 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-024-02826-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367571854 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367571854 | ||
| 003 | DE-627 | ||
| 005 | 20240423232114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-024-02826-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1384.xml |
| 035 | |a (DE-627)NLM367571854 | ||
| 035 | |a (NLM)38266761 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghilardi, Guido |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2024 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was diagnosed from a thoracic lymph node upon surgery for lung cancer. The TCL exhibited CD8+ cytotoxic phenotype and a JAK3 variant, while the CAR transgene was very low. The T cell clone was identified at low levels in the blood before CAR T infusion and in lung cancer. To assess the overall risk of secondary primary malignancy after commercial CAR T (CD19, BCMA), we analyzed 449 patients treated at the University of Pennsylvania. At a median follow-up of 10.3 months, 16 patients (3.6%) had a secondary primary malignancy. The median onset time was 26.4 and 9.7 months for solid and hematological malignancies, respectively. The projected 5-year cumulative incidence is 15.2% for solid and 2.3% for hematological malignancies. Overall, one case of TCL was observed, suggesting a low risk of TCL after CAR T | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Fraietta, Joseph A |e verfasserin |4 aut | |
| 700 | 1 | |a Gerson, James N |e verfasserin |4 aut | |
| 700 | 1 | |a Van Deerlin, Vivianna M |e verfasserin |4 aut | |
| 700 | 1 | |a Morrissette, Jennifer J D |e verfasserin |4 aut | |
| 700 | 1 | |a Caponetti, Gabriel C |e verfasserin |4 aut | |
| 700 | 1 | |a Paruzzo, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Jaryse C |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Elise A |e verfasserin |4 aut | |
| 700 | 1 | |a Susanibar Adaniya, Sandra P |e verfasserin |4 aut | |
| 700 | 1 | |a Svoboda, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Nasta, Sunita D |e verfasserin |4 aut | |
| 700 | 1 | |a Ugwuanyi, Ositadimma H |e verfasserin |4 aut | |
| 700 | 1 | |a Landsburg, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Fardella, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Waxman, Adam J |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Emeline R |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Vrutti |e verfasserin |4 aut | |
| 700 | 1 | |a Pajarillo, Raymone |e verfasserin |4 aut | |
| 700 | 1 | |a Kulikovskaya, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Lieberman, David B |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Adam D |e verfasserin |4 aut | |
| 700 | 1 | |a Levine, Bruce L |e verfasserin |4 aut | |
| 700 | 1 | |a Stadtmauer, Edward A |e verfasserin |4 aut | |
| 700 | 1 | |a Frey, Noelle V |e verfasserin |4 aut | |
| 700 | 1 | |a Vogl, Dan T |e verfasserin |4 aut | |
| 700 | 1 | |a Hexner, Elizabeth O |e verfasserin |4 aut | |
| 700 | 1 | |a Barta, Stefan K |e verfasserin |4 aut | |
| 700 | 1 | |a Porter, David L |e verfasserin |4 aut | |
| 700 | 1 | |a Garfall, Alfred L |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Stephen J |e verfasserin |4 aut | |
| 700 | 1 | |a June, Carl H |e verfasserin |4 aut | |
| 700 | 1 | |a Ruella, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 30(2024), 4 vom: 01. Apr., Seite 984-989 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:4 |g day:01 |g month:04 |g pages:984-989 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-024-02826-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 4 |b 01 |c 04 |h 984-989 | ||